Kenshodo, a Japanese pharmaceutical company, has found a great cure for economic blues: Chinese herbal medicine. And it has its sights set on the London Stock Exchange’s Alternative Investment Market (Aim) for its first market listing.
The move comes as a surprise since the company’s stock is not even listed in Japan. But Japan does not have a reputation for supporting its smaller companies.
Aim was chosen for a number of reasons. First, Kenshodo plans to expand its business in Europe and should start exporting its products to the UK and elsewhere in Europe by the end of the year.
Access intelligence that drives action
To unlock this research, enter your email to log in or enquire about access
